| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Feb, 2026 | Feb, 2026 |
| Sales | 450 | 630 | 680 | 0 | 0 |
| Sales Growth | -28.57% | -7.35% | unch | unch | unch |
| Net Income | -660 | -240 | 80 | 0 | 0 |
| Net Income Growth | -175.00% | -400.00% | unch | unch | unch |
Pheton Holdings Ltd Cl A
(PTHL)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Pheton Holdings Ltd, through its wholly owned operating subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd., focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its lead product includes Beijing Feitian's Treatment Planning System. Pheton Holdings Ltd is based in BEIJING, China.
Fiscal Year End Date: 12/31